← Back to Home

Stemline licenses oral cancer immunotherapy in deal potentially worth $1.1 billion

Georgiamune’s GIM-621 remains in preclinical development, but Menarini subsidiary Stemline has secured global development rights. The deal includes $45 million in upfront and near-term payments, while its substantial potential total remains contingent on subsequent research, development and commercial milestones.

By SURL BioNews

The next path for cancer immunotherapy may lie in an oral small-molecule drug. Italy’s Menarini Group and its subsidiary Stemline announced on October 22 that they had obtained an exclusive global license to Georgiamune’s drug candidate GIM-621, adding a cancer immunotherapy that has yet to enter human trials to their development portfolio.

Under the terms announced by the companies, Stemline obtains development, manufacturing and commercialization rights to GIM-621; Georgiamune will receive a combined $45 million in upfront and near-term payments. If subsequent preclinical, development, regulatory and commercial milestones are achieved, the deal’s potential total value could reach $1.1 billion, plus sales royalties. This ceiling is not an amount payable at signing, and the announcement did not disclose how the $45 million is divided between upfront and near-term payments.

GIM-621 is positioned as an oral small-molecule immunotherapy with potential applications across multiple solid tumors. Georgiamune’s research focuses on mechanisms that control immune cell activation, suppression and balance, with the aim of altering immune responses. However, the announcement did not disclose GIM-621’s specific molecular target or provide experimental data sufficient to assess its antitumor effects, making it difficult at present to determine how it differs substantively from existing immunotherapies.

This program should also be distinguished from Georgiamune’s other drugs. The company already has three clinical-stage programs: GIM-407, an oral regulatory T-cell activator for autoimmune diseases, and GIM-122, a bifunctional antibody, and GIM-531, an oral regulatory T-cell inhibitor, both for cancer. Their respective mechanisms cannot be directly attributed to GIM-621.

For Stemline, the license adds an early-stage candidate to its solid tumor pipeline; for Georgiamune, the partnership brings in established oncology drug development and commercialization resources. Menarini said GIM-621 complements its solid tumor portfolio, but the announcement did not specify a timeline for starting the first human trial or which cancer types would be prioritized for development.

The deal establishes the direction of the partnership, while its medical value remains to be determined through research. An oral formulation does not in itself mean greater safety or efficacy. Whether GIM-621 can achieve appropriate drug exposure in humans, produce antitumor effects and maintain an acceptable side-effect profile remains to be clinically validated.

References

  1. Fierce Biotech